Russell Conley CEO GI Cancer Institute

An update from CEO Russell Conley: May 2019

Hi supporters,

Good news – the survival rates for all ten GI cancers are rising. This hasn’t been due to a silver bullet or a miracle cure, but the dedication and support that you and all of our supporters have shown.
However, there is still work to be done. Around 28,900 Australians are diagnosed with a GI cancer each year and 38 Australians die from one each day. Your support is crucial if we are going to continue to provide life-saving treatments to these people.
Please consider making a donation before June 30 – 100% of the donations we receive go directly to GI cancer research.
The doctors who run our trials are all volunteers. They dedicate their time to conducting research because of the impact it has on the lives of patients like Jim Kershaw, featured in this edition of The Digest. The GI Cancer Institute is developing trials like the DYNAMIC-III trial to provide cutting-edge treatments and technology to people who are diagnosed with bowel cancer.

The doctors who run our trials are all volunteers. They dedicate their time to conducting research because of the impact it has on the lives of patients like Jim Kershaw, featured in this edition of The Digest. The GI Cancer Institute is developing trials like the DYNAMIC-III trial to provide cutting-edge treatments and technology to people who are diagnosed with bowel cancer.

This is one of three DYNAMIC studies, where ‘liquid biopsy’ technology is used to locate circulating tumour DNA in the blood. The GI Cancer Institute is also using this technology in the LIBERATE study to find out whether bowel cancers have the RAS genetic mutation, which needs different treatment to other types of cancer.

I would like to thank you for your continued support as we continue to improve survival rates and quality of life for people with GI cancers. I look forward to sharing our progress with you throughout 2019.

Sincerely,

Russell Conley
Chief Executive Officer

Share